1
Thirteen of 14 patients with available karyotyping data had a complex karyotype.
2
A complex karyotype was associated with worse response rates and OS.
3
Treatment outcomes of complex karyotype patients receiving chemotherapy are very poor.
4
The presence of complex karyotype and fibrosis in MDS are associated with unfavourable outcome.
5
They show a complex karyotype without any specific genetic hallmark.
6
Conclusion: The findings were consistent with transformation of ET to MDS with fibrosis and complex karyotype.
7
Prognostic impact of many abnormalities could not be determined independently because of their association with complex karyotype.
8
We propose a treatment paradigm for this uncommon subset of AML based on advanced age and complex karyotype.
9
Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only.
10
The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.
11
Case report: We described a patient with ET whose disease evolved into MDS with fibrosis and complex karyotype after 15 years of stable disease.
12
Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration.
13
The third subgroup with poor prognosis consisted of 28 patients with changes of chromosomes 3, 5, 7, 11 and complex karyotype.
14
One CR and 3 marrow-CRs were seen in patients with complex karyotypes.
15
It is characterized by extremely complex karyotypes and high frequency of chromosomal amplifications.
16
A substantial portion of these tumors exhibits complex karyotypes and lack characterized chromosomal aberrations.
